A Phase 3 open-label, randomized, controlled, global study of Telisotuzumab Vedotin (ABBV-399) versus Docetaxel in subjects with previously treated c-Met+, EGFR wildtype, locally advanced/metastatic non-squamous non-small cell lung cancer